NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN) is a publicly traded Healthcare sector company. As of May 21, 2026, NRSN trades at $0.87 with a market cap of $27.81M and a P/E ratio of 0.00. NRSN moved +8.36% today. Year to date, NRSN is -7.99%; over the trailing twelve months it is -50.31%. Its 52-week range spans $0.63 to $2.60. Analyst consensus is strong buy with an average price target of $6.50. Rallies surfaces NRSN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NeuroSense Prices 750,000-Share PIPE at $0.80, Raising $600K with Insider Support: NeuroSense Therapeutics has agreed to sell 750,000 ordinary shares at $0.80 each in a private placement, raising $600,000 at a 6.7% premium to April 27 closing. CEO Alon Ben-Noon, CFO Or Eisenberg and a major shareholder each committed $200,000 with proceeds earmarked for general corporate purposes.
| Metric | Value |
|---|---|
| Price | $0.87 |
| Market Cap | $27.81M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.60 |
| 52-Week Low | $0.63 |
| Volume | 450 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover NRSN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.50.